[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612316":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":40,"centralContacts":45,"locations":51,"responsibleParty":70,"collaborators":11,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":11,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":11,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":11,"overallStatus":53,"whyStopped":11,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Beijing InnoCare Pharma Tech Co., Ltd.","INDUSTRY",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"ICP-332 Dose A","EXPERIMENTAL",null,[13],"Drug: ICP-332 Tablets",{"label":15,"type":10,"description":11,"interventionNames":16},"ICP-332 Dose B",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"ICP-332 Dose C",[13],{"label":21,"type":22,"description":11,"interventionNames":23},"ICP-332 Placebo","PLACEBO_COMPARATOR",[24],"Other: ICP-332 Placebo Tablets",[26,31,33,35],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"DRUG","ICP-332 Tablets","ICP-332 will be administered as tablet for 12 weeks",[9],{"type":27,"name":28,"description":29,"armGroupLabels":32,"otherNames":11},[15],{"type":27,"name":28,"description":29,"armGroupLabels":34,"otherNames":11},[18],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"OTHER","ICP-332 Placebo Tablets","Placebo will be administered as tablet for 12 weeks",[21],[41],{"name":42,"affiliation":43,"role":44},"Yuling Shi","Shanghai Dermatology Hospital","PRINCIPAL_INVESTIGATOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":11,"email":50},"Molly Lin","CONTACT","+86 15198230043","molly.lin@innocarepharma.com",[52],{"facility":43,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"RECRUITING","Shanghai","Shanghai Municipality","200443","China","CN",{"type":60,"coordinates":61},"Point",[62,63],121.45806,31.22222,{"lat":63,"lon":62},[66],{"name":67,"role":48,"phone":68,"phoneExt":11,"email":69},"Yuling Shi, M.D.","021-36803154","shiyuling1973@126.com",{"type":71,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100612316","phase-2-efficacy-and-safety-of-icp-332-versus-placebo-in-participants-with-moderate-to-severe-plaque-psoriasis-100612316",false,"NCT07251998","Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ICP-332 in Patients With Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n1. Subjects voluntarily participate in this study and have signed the Informed Consent Form (ICF).\n2. Male or female subjects aged ≥ 18 years and ≤ 70 years\n3. A history of plaque psoriasis for ≥6 months at baseline\n4. Meet the following three criteria:\n\n   1. Psoriasis Area and Severity Index (PASI) score ≥12\n   2. Static Physician's Global Assessment (sPGA) score ≥3\n   3. Psoriasis affected Body Surface Area (BSA) ≥10%\n5. The subject requires systemic treatment and\u002For phototherapy.\n\nExclusion Criteria:\n\n1. Diagnosed with non-plaque psoriasis.\n2. Subject had laboratory values meeting any of the protocol-specified criteria at Screening.\n3. Presence of clinically serious, progressive, or uncontrolled disease.\n4. Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).\n5. Pregnant or lactating women.\n6. The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.","ALL","18 Years","70 Years",{"count":83,"type":84},172,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.",[90],"Plaque Psoriasis","2025-12-24",{"date":93,"type":94},"2025-12-31","ACTUAL",{"date":96,"type":94},"2025-12-22",{"date":98,"type":84},"2027-05",{"name":5,"class":6},1]